Axsome Therapeutics says SYMBRAVO achieves primary endpoint in EMERGE trial
Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP ...
Truist Financial Remains a Buy on Axsome Therapeutics (AXSM)
Truist Financial analyst Joon Lee maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today. The company’s shares closed ...
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
Q1 EPS Forecast for Axsome Therapeutics Decreased by Analyst
Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued ...
What’s Going on in the Pharma Sector?
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...